Skip to main content

Main navigation

  • Expertise
  • Publications & Insights
  • People
  • Careers

Secondary navigation

  • Value added services
  • CSR
  • About us

SearchSearch results for: “”

196 results

Stibbe advises Mylan

Stibbe advises global pharmaceutical company Mylan on the merger control aspects of its USD 7.2 billion acquisition of Swedish drugmaker Meda.

Stibbe advises Aedifica

Stibbe advises Aedifica, a Belgian listed company investing in health care real estate, on reaching agreement to acquire two new senior housing sites in Lochem and Rotterdam.

Stibbe advises Aedifica

Stibbe advises Aedifica, a Belgian listed company investing in health care real estate, on the acquisition of a new senior housing site in Arnhem.

This is the second investment of Aedifica in The Netherlands. Aedifica has developed a portfolio of health

Stibbe advises Sonova Holding AG

Stibbe has advised Sonova Holding AG on its acquisition of AudioNova B.V. from HAL Investments. The value of AudioNova is EUR 830 million.

Stibbe advises Egeria

Stibbe advises Egeria on the sale of its 40% interest in railroad maintenance company ASSET Rail to Arcadis and Dura Vermeer.

Stibbe advises Aedifica

Stibbe advises Aedifica, a Belgian listed company investing in health care real estate, on its acquisition of four senior housing sites in The Netherlands.

Stibbe represents CEO of Royal Brinkers group of companies

Stibbe represented the director and sole shareholder of the Royal Brinkers group of companies in a insolvency litigation matter. In 2010, the majority of entities within the Royal Brinkers group went bankrupt as a result of changed market conditions.

Stibbe represents Mylan

On 27 July 2015, Teva Pharmaceutical Industries announced that it has withdrawn its previously announced hostile bid to acquire Mylan N.V. Stibbe represented Mylan in this successful takeover defence and advised Mylan on both litigation and EU competition

Stibbe advises Tornier

Stibbe advises Tornier N.V. on its merger with Wright Medical Group, Inc. in an all stock transaction with a combined equity value of approximately $3.3 billion.

Stibbe advises Mylan

Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business.

Stibbe advises Aedifica

Stibbe advised Aedifica recently on two transactions in order to further expand her Dutch portfolio of care assets.

Stibbe advises Aedifica

Stibbe advises Aedifica on the acquisition of a care residence that will be constructed in Leersum. Aedifica acquired the full property of the site from Woudenburcht B.V., a local real estate developer. See for the press release here.

Stibbe represents Simed in dispute with Slotervaart hospital

Stibbe represented Simed International in a dispute with the privately-owned Slotervaart hospital in Amsterdam. The Slotervaart hospital claimed that Simed International had sent incorrect invoices to the Slotervaart hospital, which would therefore have b

Stibbe represents Supervisory Board members of FC Twente

Stibbe represented members of the Supervisory Board of the Dutch professional football club FC Twente when the club faced financial difficulties in 2016.

Stibbe advises client in the pharmaceutical sector

Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products.

Stibbe advises Zeeland Seaports on the bankruptcy of Thermphos

Stibbe advises N.V. Zeeland Seaports ("ZSP") on the bankruptcy of Thermphos International B.V. ("Thermphos"), one of the world's largest producers of phosphorus before it was declared bankrupt in November 2012.

Stibbe advises Merin (formerly Uni-Invest)

Advising Merin (formerly Uni-Invest) on the restructuring of its of its approximately EUR 790 million outstanding CMBS and Mezzanine loans and the sale of the company to Patron Capital and TPG Capital.

Stibbe advises Forbion Capital Partners

Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding.

Pagination

  • Previous page
  • Page 8
  • Page 9
  • Current page 10
  • Page 11
  • Next page
Reset filters
Date
Content type
  • Article (64)
  • Event (7)
  • Inside Stibbe (6)
  • Matter (67)
  • Podcast (4)
  • People (48)
Expertise
  • (-) Healthcare and Life Sciences (85)
  • (-) Restructuring and Insolvency (115)
  • Audit Firms and Accountancy (76)
  • Banking and Finance (422)
  • Capital Markets (243)
  • Compliance, Sanctions and Risk (163)
  • Corporate and M&A (855)
  • Corporate Investigations (31)
  • Criminal Law and Enforcement (141)
  • Digital Economy (106)
  • Employment, Benefits and Pensions (407)
  • Energy, Industry and Climate (310)
  • Environment and Planning (871)
  • ESG & Sustainability (288)
  • EU and Competition Law (488)
  • Financial Regulation (167)
  • Infrastructure and Mobility (193)
  • Insurance (36)
  • Intellectual Property (117)
  • Investment Funds (136)
  • Litigation and Arbitration (421)
  • Privacy and Data Protection (202)
  • Private Equity (196)
  • Procurement Law (122)
  • Public Law (1171)
  • Real Estate (466)
  • Sports (25)
  • Stibbe StartsUP (29)
  • Tax (438)
  • Technology, Media and Telecommunications (327)
  • Unfair Competition and Consumer Protection (186)
Jurisdiction
  • BE Law (34)
  • EU Law (17)
  • LU Law (9)
  • NL Law (110)
Language
  • Dutch (24)
  • English (170)
  • French (2)

Footer main navigation

  • Expertise
  • Publications & Insights
  • People
  • Careers
© 2025 Stibbe

Footer navigation

  • Contact
  • Disclaimer
  • General Conditions
  • Register of legal practice areas
  • Privacy and Cookie Policy
  • Cookies Settings
  • Important Information